Navigation Links
Karkus Nominees Caution Quigley Shareholders Not to be Fooled by the Company's Latest Announcement
Date:5/19/2009

WOODMERE, N.Y., May 19 /PRNewswire/ -- The Quigley Corporation (Nasdaq: QGLY) announced yesterday that its Board was exploring various options, including hiring an investment banker and exploring "strategic alternatives".

Ted Karkus, Mark Burnett, John DeShazo, Mark Frank, Louis Gleckel, MD, Mark Leventhal, and James McCubbin ("the Shareholder Nominees") believe that the recent announcement is an 11th hour attempt to obtain shareholder votes and is further evidence of the need for a slate of new highly qualified directors to protect the interests of all shareholders.

"Shareholders should ask why the incumbents released this announcement just two days before the shareholder meeting," commented Mr. Karkus. "A responsible Board should always be reviewing the Company's strategic alternatives," he added.

Ask yourself if you want the same Board that managed the Darius/Innerlight sale last year to execute any further "strategic alternatives". The Darius/Innerlight division was sold for a mere $1 million just before it turned around in early 2008. Please read our last press release which summarizes some of the many facts that trouble us with that transaction.

And, finally, ask yourself why they didn't pursue these "strategic alternatives" when the Company's OTC division had increasing sales and increasing profits, instead of now, when the division is likely to be worth significantly less, given declining sales, increasing losses and a weaker environment for selling assets.

For more information on the actions by Quigley management that have necessitated this proxy contest and the Federal Court's decision to reject Quigley's claims against the Shareholder Nominees, shareholders should refer to our previous press releases and the court order which are available at

SOURCE Ted Karkus
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. The Quigley Corporation Issues Open Letter to Stockholders; Urges Stockholders to Reject Dissident Ted Karkus Solicitation Efforts
2. Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan
3. Judge Rejects Quigleys Claims - Karkus Director Candidates Prevail in Federal Court
4. Lab Series(R) Skincare For Men Spa Indulges the 2007 Primetime Emmy(R) Nominees at the Sofitel(R) Los Angeles
5. Erie Indemnity Announces Nominees for Board of Directors
6. LCA-Vision Announces Termination of Consent Solicitation and Withdrawal of Dissident Slate of Director Nominees
7. Tennenbaum Encourages Shareholders to Vote the Blue Proxy for Tennenbaum Director Nominees at Online Resources Annual Meeting as Recommended by Riskmetrics/ISS and Proxy Governance
8. MMI Investments Issues Letter to Chemed Stockholders Illustrating the Superior Qualifications of the MMI Nominees
9. Vanda Pharmaceuticals Announces Withdrawal of Director Nominees and Proposal to Liquidate Submitted by Tang Capital
10. Americans United for Life Announces Legal Prospectus on Probable Supreme Court Nominees
11. Support Bristols Highly Qualified Independent Nominees for Advocat Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 The Special Olympics Missouri ... coaches from across the state to Columbia. This state-level event ... University of Missouri and Columbia College, and at Hickman High ... Summer Games officially kick off at 7:30 p.m. Friday, May ... a Go Wild! theme, the Parade of Athletes, the culmination ...
(Date:5/21/2013)... Puroast® Low Acid Coffee has named ... Chairman of the Board. , Among the ... Johnson during his more than 30-year career was as ... Worldwide Chairman of Consumer Pharmaceuticals & Nutritionals and President ... develop and build the market for such brands as ...
(Date:5/21/2013)... VA, May 21, 2013The Journal of the ... today released its June issue, which includes a ... Pediatric Drug-Resistant Tuberculosis. It establishes standardized definitions, ... research. This is the first step as ... visibility and share evidence and resources that can ...
(Date:5/21/2013)... May 21, 2013 Children with autism showed significant ... home using everyday items such as scents, spoons and ... that a treatment known as environmental enrichment led to ... 3 and 12. Results appear online in Behavioral ... Leon randomly assigned 28 boys to one of two ...
(Date:5/21/2013)... meeting of ESHRE (European Society of Human Reproduction & ... medicine. Well over 9000 experts are expected this year, ... much of which is of great public interest. Reports ... good source of news and features. , This year,s ... in London from 7th to 10th July. , The ...
Breaking Medicine News(10 mins):Health News:Special Olympics Missouri Athletes Ready to Show Off Skills in Columbia 2Health News:Special Olympics Missouri Athletes Ready to Show Off Skills in Columbia 3Health News:Former Johnson & Johnson Executive Brian Perkins Named Chairman of Puroast® Coffee 2Health News:JPIDS: Releases consensus statement on research definitions for drug-resistant TB in children 2Health News:JPIDS: Releases consensus statement on research definitions for drug-resistant TB in children 3Health News:Enrichment therapy effective among children with autism, UCI study finds 2
... Body By Milk MVP, HOUSTON, Oct. 22 ... superstar athletes at Hightower High School. The,National Milk Mustache ... team has earned the title of Body By Milk ... part of the,first-ever nationwide Refuel Your School contest which ...
... Inc. is preparing for its next clinical trial of Cytolin, the breakthrough ... the virus. The preparations come at a time when CytoDyn, Inc. is ... expanded business activities. , ... (PRWEB) October 22, 2008 -- Although HIV ...
... with Super Antioxidant provides ... stress, ORLANDO, Fla., Oct. 21 ... India) are jointly introducing a,new organic dietary ... organic spirulina and astaxanthin in a single ...
... a method of assessing the quality of phase ... oncology conferences: EORTC-NCI-AACR (ENA) [1] and American Society ... Thursday (23 October) at the 20th ENA Symposium ... show there is room for improvement and the ...
... Capitol Hill Briefing, WASHINGTON, Oct. 21 ... and lured into prostitution as a result of ... girls are especially,vulnerable -- runaways, survivors of childhood ... developmental disability, or abuse,drugs/alcohol. They are crime victims, ...
... new moms participate, task force says , , TUESDAY, ... and health systems should encourage and promote breast-feeding, ... Services Task Force. , Members of the task ... interventions conducted in the United States and other ...
Cached Medicine News:Health News:Houston School Wins National got milk?(R) Refuel Your School Contest 2Health News:Houston School Wins National got milk?(R) Refuel Your School Contest 3Health News:CytoDyn, Inc. Prepares for New Clinical of Its First-In-Class Drug for Treating HIV/AIDS 2Health News:CytoDyn, Inc. Prepares for New Clinical of Its First-In-Class Drug for Treating HIV/AIDS 3Health News:Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as 'Lifestyle Support' for a Fast-Paced World 2Health News:Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as 'Lifestyle Support' for a Fast-Paced World 3Health News:Assessing the quality of phase I clinical trial abstracts 2Health News:Assessing the quality of phase I clinical trial abstracts 3Health News:The Hidden Crisis: Commercial Sexual Exploitation of Girls 2Health News:The Hidden Crisis: Commercial Sexual Exploitation of Girls 3Health News:Interventions to Promote Breast-Feeding Succeed 2
(Date:5/21/2013)... Fla. , May 21, 2013  Janssen ... safety results from the global Phase 3 PROMISE ... inhibitor simeprevir (TMC435) led to sustained virologic response ... in 79 percent of treatment-experienced genotype 1 chronic ... including all stages of liver fibrosis, when administered ...
(Date:5/21/2013)... , May 21, 2013  BioRestorative Therapies, Inc. ... sciences company focused on developing stem cell based therapies ... Weinreb , its President and CEO, will be ... The conference will be held on Thursday, May 30, ... E 42nd Street in New York City.  Mr. Weinreb,s ...
(Date:5/21/2013)... STAAR Surgical Company (NASDAQ: STAA ... invasive ophthalmic products, today announced that it will participate ... recent financial results and business developments with investors and ... the 38 th Annual Deutsche Bank 2013 Healthcare ... Westin Waterfront Hotel on Wednesday, May 29, 2013 at ...
Breaking Medicine Technology:Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3STAAR Surgical To Present At Upcoming Investor Conferences 2
... Medical,Technologies, Inc. (Nasdaq: RMTI ), a ... specialty pharmaceuticals focused on the end-,stage-renal-disease market ... in its Phase IIb dose-ranging study for ... drug. The Phase IIb dose-ranging study ...
... WHITE PLAINS, N.Y., Sept. 18 Millennium ... an interim analysis of a large,randomized, international ... in combination with Velcade(R) (bortezomib) showed that ... better. These patients, who are not,eligible for ...
Cached Medicine Technology:Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 2Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 3Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 4The Leukemia & Lymphoma Society is Encouraged by Promising News for Myeloma Patients 2
Ultrasonic Pachymeter UP-1000 is fast, accurate corneal thickness measurements....
... pachymeter, with compact LCD screen and optional ... portable, weighing slightly more than 2 lbs ... large liquid crystal display. The combination of ... fast precise algorithm enables measurement immediately upon ...
15 segment Vertical Prism Bar provides 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 25, 30 PD (Note: 30 PD is on the bar). 4447 xx Vertical Prism Bar....
Force 1C has a streamlined, compact design perfect for the requirements of outpatient surgery - as well as the power and performance features needed for a full range of general inpatient surgical pro...
Medicine Products: